Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial

Steenholdt, Casper; Brynskov, Jørn; Østergaard Thomsen, Ole; Kristian Munck, Lars; Fallingborg, Jan; Ambrosius Christensen, Lisbet; Pedersen, Gitte; Kjeldsen, Jens; Ascanius Jacobsen, Bent; Sophie Oxholm, Anne; Kjellberg, Jakob; Bendtzen, Klaus; Ainsworth, Mark

doi:10.1136/gutjnl-2013-305279

Public

Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial

Published in Gut • Jul 22, 2013

Authors:

Casper Steenholdt

Jørn Brynskov

Ole Østergaard Thomsen

Abstract

OBJECTIVE: Although the reasons for secondary loss of response to infliximab (IFX) maintenance therapy in Crohn's disease vary, dose intensification is usually recommended. This study investigated the cost-effectiveness of interventions defined by an algorithm designed to identify specific reasons f...

Subject

Crohn's disease

Medicine

Infliximab

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!